Chris Shibutani - Bristol Myers Squibb

Chris Shibutani, executive vice president, chief strategy officer, leads the development and advancement of the company’s long-term strategic plan to benefit patients and shareholders. He collaborates across the enterprise to align strategic priorities with operational execution and guides the company’s approach to external partnerships and institutional collaborations, fostering innovation and driving sustainable growth.

“Navigating this transformative moment in healthcare requires us to work collaboratively to unlock the full potential of innovation – bridging medicine, science and strategy to catalyze breakthroughs that redefine what’s possible for patients,” he says.

Chris joined BMS in 2025 after more than 25 years of experience in the financial services industry as an equity research analyst covering companies across the global pharmaceutical, biotechnology and medical device industries. In his most recent role, he was a managing director in the Global Investment Research division at Goldman Sachs. Previous roles include senior analyst positions at leading firms including Hambrecht & Quist, Cowen, UBS and J.P. Morgan.

Prior to his finance career, Chris was a physician. He trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center. His frontline clinical experience provided valuable insights into patient needs and therapeutic innovation that later informed his approach to evaluating the healthcare industry, investments and strategies.

Chris earned a bachelor’s degree in biology from Harvard University, an MD from Columbia University Vagelos College of Physicians and Surgeons and an MBA from Columbia Business School.

Updated June 2025